Telomir net loss narrows to $1.72 million in Q2 FY26; revenue flat at no revenue

Reuters2026/08/13 21:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Telomir Pharmaceuticals posted a net loss of USD 1.72 million for the quarter ended June 30, 2026, narrowing from USD 5.07 million.
Operating costs fell to USD 1.76 million from USD 5.07 million, driven by general and administrative expense dropping to USD 1.32 million from USD 5.03 million.
Research and development expense rose to USD 444,674 from USD 42,839 on higher pre-clinical research and RD consultant costs.
Cash and cash equivalents totaled about USD 5.2 million at June 30, 2026; operating cash outflow was USD 2.79 million for the six months.
FDA cleared the IND to start a Telomir-Zn trial in advanced or metastatic triple-negative breast cancer; cash expected to fund operations through Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037854), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Recently, Meta launched its personal AI agent product, Muse AI, marking the transition of consumer artificial intelligence from Q&A-based chatbots to an era of intelligent agents capable of independently completing real-world tasks. Goldman Sachs released a research report maintaining a “Buy” rating on Meta.

智通财经•2026/09/14 07:16